Engineering nanoparticle communication in living systems by stigmergy: An application to enhance antitumor therapy in triple-negative breast cancer
[EN] The engineering of nanoparticle communication has gained growing attention in the last years, however, efforts to communicate nanoparticles with living systems is still a barely studied emerging topic. Here, we explore a nanoparticle cooperation strategy that involves nanoparticle-cell-nanopart...
| Autores: | , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Universitat Politècnica de València (UPV) |
| Repositorio: | RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia |
| Idioma: | inglés |
| OAI Identifier: | oai:riunet.upv.es:10251/214312 |
| Acceso en línea: | https://riunet.upv.es/handle/10251/214312 |
| Access Level: | acceso abierto |
| Palabra clave: | Nanoparticle communication Mesoporous silica nanoparticles Senescence Navitoclax Palbociclib TNBC QUIMICA INORGANICA QUIMICA ORGANICA |
| Sumario: | [EN] The engineering of nanoparticle communication has gained growing attention in the last years, however, efforts to communicate nanoparticles with living systems is still a barely studied emerging topic. Here, we explore a nanoparticle cooperation strategy that involves nanoparticle-cell-nanoparticle communication in vivo through stigmergy (a strategy in which nanodevices communicate by modifying the environment). First, mesoporous silica nanoparticles loaded with the senescence inductor palbociclib and coated with a heterobifunctional poly(ethylene glycol) that binds covalently to a MUC1-binding aptamer (NP(palbo)PEG-MUC1), is designed to specifically deliver the pro-senescent drug palbociclib in MDA-MB-231 breast cancer cells. Once the first nanoparticle modifies the environment due to the induction of senescence, a second community of nanoparticles, loaded with the senolytic navitoclax and coated with a hexa-oligo-saccharide (NP(nav)-Gal), releases its cargo to eliminate tumor senescent cells selectively. The targeted therapy through stigmergy communication is tested in vitro, and in vivo, where delays tumor growth and reduces metastases in a mouse model of human triple-negative breast cancer while minimizing undesired drugs side effects. |
|---|